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Abstract
Non–muscle-invasive bladder cancer (NMIBC) may progress
to muscle-invasive disease, but no effective preventive treatments
are available. In addition, no reliable prognostic biomarkers
have been identified. We assessed the long-term effect of the
oral retinoid fenretinide and the prognostic value of circulating
VEGF levels. We updated through the Tumor Registry the vital
status of 99 patients with resected Ta/T1 bladder tumors who
were recruited in a randomized trial of 2 years of fenretinide or
no treatment in 1993–1994. Serum VEGF levels measured at
baseline and 12 months were available in a subgroup of 62
patients. After a median of 20.5 years, 54 subjects died, 35 of any
cancer and 14 of bladder cancer. Neither overall survival (OS),
nor cancer survival (CS) or bladder cancer survival (BCS) was
affected by fenretinide (log-rank P  0.2). DNA aneuploidy in
bladder washing was associated with shorter OS (P ¼ 0.02), CS
(P ¼ 0.05), and BCS (P ¼ 0.09). Subjects with baseline VEGF
levels in the top quintile (350 pg/mL) had a significantly
shorter OS (P ¼ 0.01), CS (P ¼ 0.02), and BCS (P ¼ 0.008).
The trend across quintiles of VEGF was significant for BCS (P ¼
0.007). Multivariate analyses showed that, in addition to smok-
ing status, VEGF level in the top quintile was an independent
prognostic factor for OS (HR ¼ 2.7; 95% CI, 1.1–6.5), CS (HR
¼ 3.3; 95% CI, 1.1–9.4) and BCS (HR ¼ 8.9; 95% CI,1.3–61).
Fenretinide did not affect the long-term outcome of patients
with NMIBC. High serum VEGF level was a significant pre-
dictor of overall and cancer death and may help to identify
high-risk subjects who may benefit from a preventive therapy.
Cancer Prev Res; 9(6); 437–44. 2016 AACR.
Introduction
Bladder cancer is the fourth most common tumor in men and
the twelfth most common cancer in women in the United States,
with approximately 74,000 new cases being expected in 2015 (1).
Non–muscle-invasive bladder cancer (NMIBC) represents
about 70% to 80% of bladder neoplasms and includes low-grade
papillary forms (stage Ta), tumors invading the lamina propria
(T1) and carcinoma in situ (Tis) (2, 3). Roughly between 50%and
70%of non–muscle-invasive tumors do recur, and approximately
10% to 20% of them progress to muscle-invasive disease (4–6).
Bacillus Calmette–Guerin (BCG) intravesical immunotherapy is
the recommended treatment for high-risk, early-stage bladder
cancer, but high recurrence and progression rates (15–20%) to
muscle-invasive cancer still remain (5). Furthermore, no reliable
quantitative biomarkers that predict progression and death from
the affected target organ have been identified (7, 8).
NMIBC is an important target for the accelerated development
of new agents designed to reduce cancer incidence and mortality
(9). There is increasing need to identify risk biomarkers that are
measurable and repeatable in order to allow selection of high-risk
individuals to allow efficient drug testing in chemoprevention
clinical trials (10–12).
Based on encouraging findings from a phase IIa trial (10), in
1993 we conducted a randomized trial of the synthetic retinoid
fenretinide given orally for 2 years in patients with resected stage
T1 or Ta bladder cancer, with negative results on the primary
outcome measure, which was DNA flow cytometry in bladder
washings (13). More recently, we showed the prognostic effect of
DNA aneuploidy (i.e., DNA index > 1.1) from bladder washed
cells on disease progression and death after a median follow-up
time of 11.5 years (14).
Angiogenesis is critical for tumor growth by providing oxy-
gen, nutrients, and growth factors to the cancer cells (15).
VEGF, a homodimeric glycoprotein with a molecular weight
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of approximately 45 kDa, is considered to be a crucial regulator
of both normal and pathologic angiogenesis (16, 17). The
expression of VEGF, either in tissue and serum, has been
extensively investigated in patients with NMIBC and bladder
cancer with different findings (18–25). Retinoids have been
shown to modulate angiogenesis and to inhibit carcinogenesis
through different mechanisms, including an angiopreventive
effect (26, 27).
In the present paper, we report the results of fenretinide on
survival endpoints after a median of 20.5 years and assess the
prognostic value of circulating VEGF, which was measured in a
subgroup of patients (n ¼ 62).
Materials and Methods
Study design, subjects, and treatment
A phase IIb chemoprevention trial with fenretinide in NMIBC
started at the National Cancer Institute of Genoa in 1993. A
detailed description of the trial has been published elsewhere
(13). Briefly, 99 subjects, ages < 80, with NMIBC (stage Ta or T1,
any grade) resected within the previous 3 years, were randomized
to receive fenretinide 200 mg/day or no treatment for 2 years. An
additional year of follow-up was included to evaluate any poten-
tial rebound effect. The primary outcome measure was the flow
cytometric DNA content in epithelial cells obtained after 12
months. A detailed description of the original trial design, study
procedures, and main results has previously been described (10,
13, 28). Years later, we decided to assess the prognostic signifi-
cance of circulating VEGF and its potential surrogate effect on
survival by fenretinide modulation. Available samples from 63
subjects who had completed the first year of study and had serum
aliquots at both timepointswere identified; data fromone subject
was further excluded because of a secondmalignancy at the end of
the first year of treatment. Analysis was thus performed on
samples from 62 subjects, 29 allocated in the fenretinide and
33 in the control arm, respectively.
Assay methods
Serum concentrations of VEGF were measured on morning
fasting blood samples. Bloodwere drawn at baseline and after 12-
month treatment and serum aliquots were stored at 80C until
assayed in a single experiment at the end of the trial to minimize
analytical variability and blinded as to treatment allocation.
Serum VEGF was measured by means of a quantitative
sandwich enzyme immunoassay kit (SVE00) produced by R&D
Systems. A monoclonal antibody specific for VEGF was pre-
coated onto a 96-well microplate. Standards and samples were
dispensed into the wells in duplicate. Any VEGF present was
bound by the immobilized antibody. After washing away any
unbound substances, an enzyme-linked polyclonal antibody
specific for VEGF was added to the wells. Following washing to
remove any unbound antibody–enzyme reagent, a substrate
solution was added to the wells and color developed in pro-
portion to the amount of VEGF bound in the initial step. The
color development was stopped and the optical density was
determined on a microliter plate reader at 450 nm. A standard
curve was created by plotting the logarithm of the mean
absorbance of each standard versus the logarithm of the cyto-
kine concentration. The sensitivity of the assay was 9.0 pg/mL.
The intra-assay and inter-assay coefficients of variation were
less than 7% and 9%, respectively.
Cohort follow-up. Information on patients' health status was
ascertained from the Urology Units who participated in the trial
or, when the patient was lost to follow-up, through computer
linkage with the local Mortality Registry or by phone. Causes of
death were ascertained through death certificates or by review of
the local Mortality Registry.
Statistical analysis. The main descriptive statistics were mean and
standard deviation, median, interquartile range (IQR), and quin-
tiles for continuous factors, absolute and relative frequency for
categorical factors. The Mann–Whitney rank test was used to
compare continuous factors and Pearson c2 or Fisher exact test
were used to compare categorical factors between treatment
arms. Kaplan–Meier estimates of the cumulative probability for
overall survival (OS), cancer survival (CS), bladder cancer–spe-
cific survival (BCS), defined as the time from randomization to
death, death from cancer, death frombladder cancer, respectively,
were obtained for all the baseline factors, including allocated
treatment (fenretinide versus control), age, sex, smoking habit,
tumor stage, tumor grade, recurrence history, previous intravesical
treatment, DNA aneuploidy (DNA index < 1.1 vs.  1.1) and
VEGF baseline levels. To assess the prognostic role of VEGF and in
the absence of any validated threshold, we considered quintiles of
VEGF distribution and evaluated the clinical outcome in terms of
OS, CS, and BCS.
Multivariate Coxmodeling was used to assess the independent
prognostic effect of all factors under investigation. All covariates
were tested for the proportional hazards assumption. Starting
from a full model (i.e., including all baseline factors cited above),
we adopted a backward stepwise selection approach with a
significance cutoff level for removal from the model equal to
0.20 (Wald P value). P values were two-sided and considered
significant if <0.05; all calculations were performed using STATA
version 13 software.
Results
Patient characteristics at baseline according to the treatment
arm had been described extensively in previous publications (10,
16) and are shown in Supplementary Table S1. Briefly, the two
arms were well balanced for patient and tumor characteristics
except for a trend toward an excess of former smokers in the
fenretinide treatment arm.
Table 1 illustrates VEGF levels by the treatment arm, in the
subgroup of 62 patients who had measured this biomarker at
baseline and after 12 months from randomization. VEGF levels
were not significantly different between fenretinide-treated and
control subjects either at baseline or after 12 months. Overall, a
significant decrease of VEGF levels was observed after 12 months
(P ¼ 0.007), regardless of the treatment arm.
A comparison of subjects' characteristics according to VEGF
levels determination is shown in Table 2. Except for age, where
subjects without VEGF determination were on average 5 years
older, there was no statistically significant difference between
groups in any patients' characteristic. However, as illustrated
in Fig. 1, patients with VEGF determinations showed a trend to
an increased survival (HR 0.59 and 0.42 for OS and BCS, respec-
tively), suggesting that VEGF analysis was not performed in a
random subgroup.
After a median follow-up of 20.5 years (interquartile range,
20.3–20.8), a total of 54 subjects died, 35 of any cancer and 14 of
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bladder cancer. The distribution of VEGF levels at baseline (quin-
tiles of distribution) according to subsequent deaths is summa-
rized in Supplementary Table S2. Within the subgroup of 62 in
whomVEGF levelsweremeasured, all 6 bladder cancer deaths had
baselineVEGF levels higher thanor equal to themedian level (216
pg/mL), and 3 had VEGF levels in the top quintile (>350 pg/mL).
In univariate analyses, we tested the effect of fenretinide treat-
ment, aneuploidy in bladder washings (DNA index < 1.1 vs. 
1.1) andVEGF levels (< and the 5thquintile, 350pg/mL)onOS,
CS, andBCS. Therewas no effect of the retinoid on any of the three
outcomemeasures (Fig. 2), nor was there any interaction between
retinoid treatment and smoking status (data not shown). As
regards DNA index (Supplementary Fig. S1), the cumulative
probability of death at 20 years from any cause, any cancer and
bladder cancer was 28%, 53%, and 77% for DNA diploid wash-
ings and 60%, 71% and 88% for DNA aneuploid washings,
respectively (log-rank test P ¼ 0.02, 0.05, and 0.1, respectively).
Finally, compared with subjects in quintiles 1–4 of VEGF levels
pooled together, subjects in the top VEGF quintile had a signif-
icantly shorter OS (cumulative probability of death at 20 years:
62% vs. 33%, respectively, P¼ 0.01), CS (74% vs. 44%, P¼ 0.02)
and BCS (92% vs. 69%, P ¼ 0.008; Fig. 3). More importantly, a
statistically significant trend across ordered quintiles of VEGF was
found for BCS (P ¼ 0.007), but not for OS and CS (P ¼ 0.13 and
0.2, respectively).
Table 3 shows the results of Coxmultivariate analysis. The final
models showed that the top VEGF quintile at baseline were the
only independent predictor for all three outcomes, namely, all-
causemortality (HR¼ 2.65, 95%CI, 1.09–6.47; P¼ 0.03), cancer
mortality (HR¼ 3.27, 95%CI, 1.14–9.40; P¼ 0.03), and bladder
cancer mortality (HR ¼ 8.87, 95% CI, 1.29–61.2; P ¼ 0.03).
Smoking and T1 stage had prognostic effect on OS and CS,
respectively, whereas there was a trend toward a higher risk of
death from bladder cancer in subjects in the fenretinide arm (P¼
0.09). Adjusting for other variables, DNA index was not indepen-
dently associated with any of the mortality outcomes (P > 0.7).
Discussion
Despite recent advances in screening and multimodality ther-
apy, the outcome for advanced bladder cancer remains generally
poor, thus emphasizing the need for early detection and effective
prevention strategies as well as better prognostic and predictive
markers and tailored treatment approaches. Currently, the most
widely studied prognostic factors are related to pathologic char-
acteristics of the neoplasm, including tumor size, grade, stage, and
vascular invasion (29–32).
Angiogenesis is a multistep process and there is evidence that
the angiogenic switch, defined as the point at which a tumor is
able to induce the formation of new vessels, occurs very early
during the carcinogenesis process with VEGF being a pivotal
regulator of this event (15, 16). It thus appears plausible that
chemopreventionmay include inhibition of angiogenesis among
its potential targets (33, 34).
Our results after a median follow-up time of 20.5 years show
that 55% of subjects with NMIBC who participated in a chemo-
prevention trial of fenretinide have died, 35% of any cancer and
15% of invasive bladder cancer, supporting the notion that this is
a high-risk group in whom effective preventive interventions are
needed. Conventional clinical factors such as tumor stage and
smoking habit were associated with a greater risk of death, in line
with literature findings (35). Interestingly, we showed an intrigu-
ing trend to an association between circulating VEGF levels at
baseline and death for bladder cancer inasmuch as all of the 6
subjects who died of bladder cancer had VEGF levels above the
median value, and the half of themwere in the top VEGF quintile.
We showed a significant trend across ordered quintiles of VEGF
Table 2. Main subject characteristics by serum availability for VEGF level
determination
VEGF level
determined (n ¼ 62)
VEGF level
undetermined (n ¼ 37) Pa
Age, yearsb 60  9.5 65  7.9 0.03c
Sex
Male 48 (77.0)d 32 (86.5) 0.3
Female 14 (23.0) 5 (13.5)
Smoking habit
Non smoker 16 (25.8) 7 (18.9) 0.5
Former smoker 21 (33.9) 17 (46.0)
Current smoker 25 (40.3) 13 (35.1)
Tumor stage
pTa 37 (59.7) 21 (56.8) 0.8
pT1 25 (40.3) 16 (43.2)
Tumor grade
G1 25 (40.3) 16 (43.2) 0.6
G2 30 (48.4) 19 (51.4)
G3 7 (11.3) 2 (5.4)
Tumor history
First event 24 (38.7) 12 (32.4) 0.5
Recurrent tumor 38 (61.3) 25 (67.6)
DNA indexe
DI < 1.1 (Diploid) 25 (42.4) 10 (29.4) 0.2
DI  1.1 (Aneuploid) 34 (57.6) 24 (70.6)
Previous intravesical treatment
None 5 (8.0) 5 (13.5) 0.1
BCG 37 (59.7) 14 (37.8)
Chemotherapy 20 (32.3) 18 (48.7)
Treatment arm
Control 33 (53.2) 17 (45.9) 0.5
Fenretinide 29 (46.8) 20 (54.1)
aPearson c2 or Fisher exact test.
bMean  standard deviation.
cMann–Whitney rank test.
dNumber in parentheses are percentages.
eThree patients missed DNA index evaluation in the control group.
Table 1. VEGF levels at baseline and after 12 months by the treatment arm
(n ¼ 62)
Control (n ¼ 33) Fenretinide (n ¼ 29) Pa
Baseline, pg/mL
Mean  SD 233.3  133.4 263.1  162.1 0.4
Median (IQR) 201.3 (132.8–277.3) 245.8 (135.2–313.3)
Bottom quintile 72.2–123.1 88.2–124.6
2nd quintile 127.0–187.5 129.6–176.9
3rd quintile 189.3–229.3 217.4–254.4
4th quintile 230.3–351.8 278.2–347.6
Top quintile 371.6–608.0 423.2–741.7
After 1 year, pg/mL
Mean  SD 219.2  132.0 224.0  133.4 0.7
Median (IQR) 166.8 (136.1–268.5) 201.5 (137.5–275.3)
Bottom quintile 57.1–124.5 52.5–119.5
2nd quintile 125.0–157.6 131.8–178.6
3rd quintile 161.5–191.3 183.2–211.3
4th quintile 206.6–310.0 212.3–302.2
Top quintile 370.8–641.1 323.3–605.7
aMann–Whitney test. Difference in VEGF levels (independently from treatment
arm) between baseline and 24 months: Wilcoxon signed-rank test P ¼ 0.007.
VEGF Levels in Non–Muscle-Invasive Bladder Cancer
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Cox Model, adjusted for age: 
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Cox Model, adjusted for age: 
HR (VEGF det. vs. undet.)= 0.59; 95% CI: 0.30–1.16, P = 0.12











62 61(0) 57(1) 55(0) 52(1) 49(1) 45(0) 43(0) 40(0) 36(2) 35(1) 0(0)VEGF determined
37 34(1) 31(3) 28(0) 26(0) 24(1) 22(1) 18(2) 14(0) 13(0) 11(0) 0(0)VEGF undetermined
Number at risk





Cox Model, adjusted for age: 
HR (VEGF det. vs. undet.)= 0.42; 95% CI: 0.14–1.22, P = 0.11
Log-rank P = 0.05
Figure 1.
Kaplan–Meier OS (A), CS (B), and BCS (C)
according to VEGF determination (undetermined,
dotted line; determined, continuous line). HRs
from a Cox proportional hazards model adjusted
for age are provided.
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Log-rank P = 0.2
C
Figure 2.
Kaplan–Meier OS (A), CS (B), and BCS (C) according treatment
(fenretinide, dotted line; no treatment, continuous line).
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12 11(1) 10(1) 9(0) 8(1) 6(2) 5(0) 4(1) 4(0) 4(0) 4(0) 0(0)VEGF ≥350 pg/mL
50 50(0) 47(3) 46(1) 44(0) 43(1) 40(2) 39(0) 36(0) 32(4) 31(1) 0(0)VEGF <350 pg/mL
Number at risk




Log-rank P = 0.008
C
Test of trend across ordered quinles of VEGF: P = 0.13
Test of trend across ordered quinles of VEGF: P = 0.2
Test of trend across ordered quinles of VEGF: P = 0.007
Figure 3.
Kaplan–Meier OS (A), CS (B), and BCS (C) curves according to VEGF
values at baseline (below vs. above or equal the top quintile, i.e., 350
pg/mL). P values for test for trend across ordered quintiles of VEGF
are provided.
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with BCS only (P ¼ 0.007), supporting a biologic link between
angiogenesis and bladder carcinogenesis progression. More
importantly, high circulating levels of VEGF also had an inde-
pendent, statistically significant, prognostic effect on all mortality
endpoints after adjustment for age, stage, and smoking habit.
Specifically, VEGF level 350 pg/mL was the strongest predictor
of BCS, although the small sample size precludes any firm
conclusion, as reflected by the wide confidence interval of the
estimate.
To our knowledge this is the first report showing a prognostic
value of circulating VEGF levels in NMIBC, with not only OS but
also cancer-specific survival and BCS as endpoints, thus linking a
strong and validated angiogenesis biomarker to death for invasive
bladder cancer.
The role of VEGF in bladder carcinogenesis has extensively
been studied, but results remain inconclusive. Higher urinary
and serum VEGF levels have been associated with a greater risk
of recurrence and progression to invasive cancer in NMIBC (18,
19). Furthermore, the degree of invasiveness of NMIBC have
recently been linked to high levels of VEGF (20, 21), suggesting
a relationship between VEGF and prognosis of NMIBC (22, 23),
and a recent meta-analysis (36) of over 1,200 patients showed
that elevated VEGF expression was significantly associated with
poor prognosis, both in terms of OS (HR¼ 1.84; 95% CI, 1.23–
2.76) and disease-free survival (HR ¼ 1.50; 95% CI, 1.26–
1.79).
A strength of our observation is the long-term follow-up and
the source of data derived from a randomized clinical trial.
Moreover, in contrast to other reports, in our study, circulating
VEGF was determined in patients after TURB and therefore
possibly unrelated to the papillary tumor burden. Thus, we
hypothesize that high serum levels reflect the degree of field
cancerization in the bladder and high serum VEGFmay represent
a biomarker of imbalance between proangiogenic and antiangio-
genic factors, whichmay ultimately result in an angiogenic switch
toward proliferation of endothelial cells and the development of a
neoplastic phenotype. Additional studies are necessary to confirm
our exploratory finding. As for the significant decrease of VEGF
levels 1 year apart, we have no ready explanation for this, except
for a regression to the mean phenomenon rather than an a real
biologic effect associated with the prolonged interval from initial
TURB or an analytical artifact.
An important weakness of our analysis is the lack of VEGF
measurements in all subjects as only a subgroup of 62 had
available serum aliquots. These subjects were on average 5 years
younger and, consequently, had increased survival compared
with the 37 subjects without VEGF determination. However, age
difference does not appear to fully explain the increased survival
of this group since the association still persists after adjusting for
age, although not significantly so. The reason for this selection
bias, which clearly limits the generalizability of our findings, is
still unclear but has likely to do with the possibility that older
patients could be less likely to remain on the fenretinide trial for a
full year.
As in a previous report (14), we showed no effect of the
treatment with fenretinide (200 mg day for 2 years) on survival
endpoint. This finding is consistent with previous results suggest-
ing a lack of efficacy (13, 37) or even a detrimental effect by beta
carotene and retinoids when used to inhibit tobacco-related
carcinogenesis in large clinical trials (38, 39). We have no strong
evidence to support a detrimental effect, although a slight trend to
an increase in overall mortality was noted in the fenretinide arm,
in line with preclinical evidence of a detrimental effect of beta-
carotene in smokers (40).
In conclusion, our 20-year survival data show that fenretinide
does not affect disease outcome in subjects with NMIBC. How-
ever, we detected an inverse association between baseline VEGF
levels and BCS in our cohort of patients with resected NMIBC,
even if generalizability of our results may not be fully applicable
due to the apparent selection bias in the cohort we examined.
Because angiogenesis represents a key step in tumor progression,
and VEGF is implied in early stages of angiogenesis, its circulating
levels may represent a putative biomarker to select high-risk
patients as well as a candidate surrogate endpoint for future
chemoprevention studies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Authors' Contributions
Conception and design: M. Puntoni, R. Torrisi, A. DeCensi
Development of methodology: M. Puntoni, R. Torrisi, H. Johansson,
A. Curotto, A. DeCensi
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): S. Campora, E. Garrone, C. Defferrari, R. Torrisi,
H. Johansson, S. Bruno, A. Curotto
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): M. Puntoni, A. DeCensi
Table 3. Multivariate Cox proportional hazard model OS, CS, and BCS (n ¼ 59)a
OS CS BCS
n HR (95% CI) Pb HR (95% CI) Pb HR (95% CI) Pb
Tumor stage
pTa 36 1.0 1.0 1.0
pT1 23 1.81 (0.80–4.11) 0.16 2.75 (1.03–7.37) 0.04 4.10 (0.67–25.08) 0.13
Smoking habit
Never 15 1.0 1.0 —
Ever (current/former) 44 4.34 (1.25–15.07) 0.02 5.02 (1.10–23.02) 0.04 — —
Treatment
Control 30 — — 1.0
Fenretinide 29 — — — — 6.85 (0.74–63.79) 0.09
VEGF (at baseline)
<350 pg/mL 47 1.0 1.0 1.0
350 pg/mL (5th quintile) 12 2.65 (1.09–6.47) 0.03 3.27 (1.14–9.40) 0.03 8.87 (1.29–61.22) 0.03
aThe risk estimates are age-adjusted; we adopted a backward stepwise selection approach with a significance level equal to 0.20 for removal from the model; total
n ¼ 59 due to missing data for n ¼ 3 DNA index values.
bTwo-sided Wald test.
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